Primary Objective:~-To evaluate the efficacy of lonca as consolidation therapy in patients with relapsed or refractory LBCL who achieve PR after CAR T-cell therapy.~Secondary Objectives:~-To evaluate safety and tolerability of lonca as consolidation therapy in patients with relapsed or refractory LBCL who achieve PR after CAR T-cell therapy.~Exploratory Objective:~-To determine the pharmacodynamic effects and investigate biomarkers of response and resistance of this novel consolidation therapy.
To learn if loncastuximab tesirine (called lonca in this informed consent form) can help to control large B-cell lymphoma that is relapsed or refractory after receiving CAR T-cell therapy. The safety and possible effects of the study therapy will also be studied.